Inhibikase Therapeutics (IKT) Return on Capital Employed (2021 - 2024)
Historic Return on Capital Employed for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2024 value amounting to 0.6%.
- Inhibikase Therapeutics' Return on Capital Employed rose 9800.0% to 0.6% in Q4 2024 from the same period last year, while for Dec 2024 it was 0.6%, marking a year-over-year increase of 9800.0%. This contributed to the annual value of 0.54% for FY2024, which is 6900.0% up from last year.
- As of Q4 2024, Inhibikase Therapeutics' Return on Capital Employed stood at 0.6%, which was up 9800.0% from 11.84% recorded in Q3 2024.
- Inhibikase Therapeutics' Return on Capital Employed's 5-year high stood at 0.24% during Q3 2021, with a 5-year trough of 11.84% in Q3 2024.
- Its 4-year average for Return on Capital Employed is 1.79%, with a median of 0.77% in 2022.
- Examining YoY changes over the last 5 years, Inhibikase Therapeutics' Return on Capital Employed showed a top increase of 9800bps in 2024 and a maximum decrease of -106900bps in 2024.
- Over the past 4 years, Inhibikase Therapeutics' Return on Capital Employed (Quarter) stood at 0.37% in 2021, then tumbled by -114bps to 0.79% in 2022, then crashed by -100bps to 1.58% in 2023, then soared by 62bps to 0.6% in 2024.
- Its Return on Capital Employed was 0.6% in Q4 2024, compared to 11.84% in Q3 2024 and 3.04% in Q2 2024.